HomeBIOTECHNOLOGY

BIOTECHNOLOGY

ndd Medical Technologies Reports New Inline Filters Offer Additional Protection Against COVID-19 During Lung Function Tests

Ensuring an added level of safety, the new filters can be used with ndd’s revolutionary, and highly portable EasyOne® spirometry range, including the EasyOne Air, EasyOne Pro, and EasyOne Pro LAB.

Sonde Health Launches New Voice-Enabled Health Screening Tool to Help Employers Return to Work During the Global Pandemic

The new voice-enabled health detection and monitoring app from Sonde Health promises to potentially help employers improve employee safety, meet government mandates, and satisfy their own administrative needs as they reopen office doors in a rapidly changing COVID-19 environment.

AnPac Bio-Medical Science Signs a Record Multi-Million Dollar Contract for Cancer Screening with Beijing Yuan Jian Health Management Co., Ltd. in China

This contract contains a minimum of 76,000 paid cancer screening tests, including at least 6,000 paid tests in 2020, 25,000 paid tests in 2021, and 45,000 paid tests in 2022.

Novotech Partners with South Korea’s Pusan National University Hospital

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region.

Abingdon Health Announces Its Latest Expansion and Additional Manufacturing Capacity

This will provide a significant increase in its manufacturing footprint, resulting in Europe’s largest capacity for rapid test manufacturing. This news comes weeks after the UK Government announced Abingdon Health as one of the leading members of the UK Rapid Test Consortium

SARS-CoV-2 PCR Assay Now Approved for Human Saliva Specimens

Validation of its CE-IVD UltraGene® Combo2Screen SARS-CoV-2 qPCR assay to be used straight from non-invasive fluid saliva samples and allowing for broad population screening.

Redox and Curative Partner to Connect COVID-19 Test Results to Public Health Departments

Since formalizing the partnership in May, the duo has kicked off projects with 24 states, with two, Illinois and Delaware, now fully live.

Creatv Microtech Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer (NSCLC) using a Simple Blood Test

“We are delighted to present a method to stratify patients responding to immunotherapy by a single tube of blood collected after completion of CRT,” said Dr. Cha-Mei Tang, CEO of Creatv. “Early identification of patients that do not respond to immunotherapy will reduce unnecessary patient suffering from ineffective and costly treatment, allowing patients to proceed to alternative therapies.” Currently, no other blood test can predict immunotherapy treatment response for lung cancer.

Fibralign Announces Strategic Partnership With Terumo

This agreement is an outcome of an ongoing collaboration between Fibralign and Terumo where the two companies have agreed to partner in efforts to commercialize BioBridge in Japan.
Exit mobile version